Cancer Home > Mutamycin and Pregnancy
Classified as a pregnancy Category D medication, Mutamycin (mitomycin) caused birth defects and miscarriages during animal studies. Therefore, it should only be given to a pregnant woman if the benefits to the mother outweigh the risks to her unborn child. It is generally not recommended to give this medicine during pregnancy.
Can Pregnant Women Receive Mutamycin?
Mutamycin® (mitomycin) is an intravenous (IV) medication used in the treatment of certain types of cancer. It is a pregnancy Category D medication, which means it may be harmful to a fetus if given to a pregnant woman.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Mutamycin is classified as a pregnancy Category D medication.
Pregnancy Category D is given to medicines that have been shown to present a risk to the fetus in studies of pregnant women but may still offer benefits that outweigh the risks the drug presents. A pregnancy Category D medicine may still be given to a pregnant woman if her healthcare provider believes that the benefits to the woman outweigh the possible risks to her unborn child.
While Mutamycin has not been systematically studied in pregnant women, the drug caused a variety of problems in animal studies. In these studies, Mutamycin increased the risk for miscarriage and decreased the weight of the fetuses when given to pregnant rats and mice in doses lower than the equivalent recommended human dose. It also caused a number of birth defects, including:
- Club foot
- Cleft palate
- Incomplete bone development
- Defects of the toes, fingers, and reproductive organs.
In general, Mutamycin is not recommended for use in pregnant women. However, there may be cases where a healthcare provider recommends the medication during pregnancy, such as in women who need cancer treatment and are not adequately responding to safer medications.